These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 4686226)

  • 41. [Effect of a decarboxylase inhibitor (Ro 4-4602) and L-dopa on inhibited depressions. II. Experimental psychological studies].
    Pohlmeier H; Schön I; Matussek N
    Arzneimittelforschung; 1970 Jul; 20(7):932-3. PubMed ID: 4918920
    [No Abstract]   [Full Text] [Related]  

  • 42. [Familial syndrome with parkinsonian tremor and anosmia and its therapy with L-dopa associated with a decarboxylase inhibitor].
    Constantinidis J; de Ajuriaguerra J
    Therapeutique; 1970 Mar; 46(3):263-9. PubMed ID: 5422192
    [No Abstract]   [Full Text] [Related]  

  • 43. Coupling of hypotensive and anit-Parkinson effects with two dopaminergic drugs.
    Düby SE; Dahl LK; Cotzias GC
    Trans Assoc Am Physicians; 1971; 84():289-96. PubMed ID: 5164305
    [No Abstract]   [Full Text] [Related]  

  • 44. [Treatment of Parkinson's disease: L-dopa or stereotaxic technics?].
    Krayenbuhl H; Siegfried J
    Neurochirurgie; 1970; 16(1):71-6. PubMed ID: 4911157
    [No Abstract]   [Full Text] [Related]  

  • 45. L-Dopa therapy of Parkinson's disease. (A review of the preliminary experience at West Virginia University).
    Gutmann L; Martin JD; Gutrecht JA
    W V Med J; 1970 Apr; 66(4):109-11. PubMed ID: 5264660
    [No Abstract]   [Full Text] [Related]  

  • 46. Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.
    Rinne UK; Sonninen V; Sirtola T
    Z Neurol; 1972; 202(1):1-20. PubMed ID: 4114458
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
    Dupont E; Hansen E; Melsens S; Parkenberg H; Holm P
    Acta Neurol Scand Suppl; 1972; 51():115-7. PubMed ID: 4514334
    [No Abstract]   [Full Text] [Related]  

  • 48. [Modalities of treatment of Parkinsonian syndrome with L-dopa].
    Yanniotis G; Eisenring JJ; Gauthier G; Tissot R; de Ajuriaguerra J
    Int J Neurol; 1972; 9(1):23-32. PubMed ID: 5086635
    [No Abstract]   [Full Text] [Related]  

  • 49. [Indications and results of monoamine treatment in parkinsonian syndromes].
    Boudin G; Pépin B; Guillard A; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1972 Jul; 127(1):79-97. PubMed ID: 4520464
    [No Abstract]   [Full Text] [Related]  

  • 50. Modification of levodopa effect by systemic decarboxylase inhibition.
    Mars H
    Arch Neurol; 1973 Feb; 28(2):91-5. PubMed ID: 4683155
    [No Abstract]   [Full Text] [Related]  

  • 51. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 52. [Therapy of Parkinson's syndrome with L-dopa only and in combination with a decarboxylase inhibitor. A comparison].
    Feise G; Paal G
    Nervenarzt; 1974 Mar; 45(3):126-32. PubMed ID: 4832035
    [No Abstract]   [Full Text] [Related]  

  • 53. Therapeutic guidelines and side effects encountered during L-dopa therapy in 100 cases of parkinsonism.
    Jenkins AC; Schwieger AC
    Med J Aust; 1971 Oct; 2(14):693-700. PubMed ID: 5114186
    [No Abstract]   [Full Text] [Related]  

  • 54. [Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
    Geissbuhler F; Eisenring JJ; Friedli P; Bartholini G; Tissot R
    Encephale; 1972; 61(2):127-48. PubMed ID: 4634903
    [No Abstract]   [Full Text] [Related]  

  • 55. Parkinson's disease treated with L-dopa. Three-year follow-up report.
    Mones RJ
    N Y State J Med; 1972 Nov; 72(22):2749-50. PubMed ID: 4510706
    [No Abstract]   [Full Text] [Related]  

  • 56. [Results of treatment of Parkinsonism with L-dopa].
    De Divitiis E; D'Andrea F; Signorelli CD
    Sist Nerv; 1970; 22(2):99-108. PubMed ID: 5504563
    [No Abstract]   [Full Text] [Related]  

  • 57. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 58. [Treatment of Parkinson's disease with L-dopa. 77 cases].
    Boudin G; Castaigne P; Lhermitte F; Beck H; Guillard A; Marteau R; Pepin B; Rondot P; Raphy B
    Rev Neurol (Paris); 1970 Feb; 122(2):89-102. PubMed ID: 4931719
    [No Abstract]   [Full Text] [Related]  

  • 59. [L-DOPA with the decarboxylase inhibitor Ro 4-4602 in the treatment of Parkinson's disease].
    Lakke JP; Nienhuis RJ; Meyer R; Zwols F; Schut T
    Ned Tijdschr Geneeskd; 1972 Nov; 116(48):2180-4. PubMed ID: 4639072
    [No Abstract]   [Full Text] [Related]  

  • 60. [Dopamine and abnormal movements].
    Rondot P; Dumas RJ
    Rev Neurol (Paris); 1972 Jul; 127(1):99-113. PubMed ID: 4272134
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.